Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I’m lost on Quilter and glad they are out to be honest. I write to the company Monday to enquire just out of interest
We note that hedge funds don’t have a meaningful investment in Tiziana Life Sciences. Our data suggests that Gabriele Marco Cerrone, who is also the company’s Top Key Executive, holds the most number of shares at 47%. When an insider holds a sizeable amount of a company’s stock, investors consider it as a positive sign because it suggests that insiders are willing to have their wealth tied up in the future of the company. The second and third largest shareholders are Quilter Investors Limited and HighTower Advisors, LLC, holding 24% and 4.3%, respectively.
Our analysis suggests that the top 2 shareholders collectively control 71% of the company’s shares, implying that they have considerable power to influence the company’s decisions.
And this at back end of 2017 and start of 2018 would have suppressed the price for some time I’d guess.
RNS Number : 3791L
Tiziana Life Sciences PLC
19 April 2018
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Subscription raising £825,000
London, April 19, 2018 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces that it has raised £825,000 in cash by the issue of 1,031,250 new ordinary shares at a price of 80p per share. In addition, the Company has issued 51,563 new ordinary shares credited as fully paid and 51,563 warrants exercisable at a price of 80p per share to intermediaries in lieu of commissions on the funds raised.
The Company has undertaken a number of smaller fund raises over past year to provide it with its working capital requirement. As the Company is at pre-revenue stage and engaged in research and development, it continues to be reliant on raising further funds in the equity markets to provide it with its on-going working capital requirement.
Application has been made to the London Stock Exchange to admit the 1,082,813 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 23 April 2018. The new ordinary shares will rank pari passu with the existing ordinary shares. Following the issue of shares detailed above the so enlarged issued share capital of the Company will comprise 126,904,285 ordinary shares of 3p each.
The Company has granted options over a total of 10,717,403 ordinary shares of which 5,085,833 are vested at exercise prices between 15p and £1.25p per share and 5,631,570 remain subject to vesting conditions (at potential exercise prices ranging from 15p to £1.925 per share). In addition warrants to subscribe for a total of 5,060,809 ordinary shares at exercise prices between 50p and £2.50 are outstanding (including the warrants referred to above).
Therefore the fully diluted issued share capital of the Company is 142,682,497 ordinary shares (assuming all options and warrants, vested and unvested, exercised and exercisable, were converted).
In conformity with DTR 5.6.1 the Company notifies that as at the date of this announcement, it has a single class of shares in issue being ordinary shares of 3 pence each ("Ordinary Shares") and that following the issue of the 1,082,813 Ordinary Shares referred to above, the total number of Ordinary Shares in issue will be 126,904,285. There are no Ordinary Shares held in Treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.
This figure of 126,904,285 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under th
So it seem quilter ended up getting the shares not because they wanted them but as some sort debt or security repayment?
I found this on Quilter though.
TR-1 - Notification of Major Holdings
New York/London, 15 April 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today releases the TR-1 forms appended to this announcement.
The Company understands that the resultant stake in its share capital held by Quilter plc, as nominee for certain underlying shareholders, is due to the transfer of existing shareholdings from Beaufort Securities Limited (in administration), and not due to any recent on-market purchases.
I walked through the RNS going back in time weeks ago and I couldn’t see any obvious reason, no warnings etc. The main thing I could see is all the areas that cover have moved forward a lot and cost a lot to get here now. Plus no StemprintER.
Alwaysone
I thin uv walked into this question. why did it drop to such low levels?
Don’t forget he had the share price at above £2 in 2015/16. Even a small share placing at £1.60. The difference now is all the elements to the company have advanced and StemprintER wasn’t part of this price then.
Fri, 15th Dec 2017 07:00
RNS Number : 4366Z
Tiziana Life Sciences PLC
15 December 2017
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Placing to raise £200,000 and issue of equity
London, December 15, 2017 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces that it has raised £200,000 through the issue of 133,333 new ordinary shares ("Placing Shares") at a price of 150p per share (the "Placing"). Each Placing Share has a warrant attached entitling the holder to subscribe for one new ordinary share at an exercise price of 160p per share, exercisable until 15 December 2022. Fees in connection with the Placing are to be satisfied through the issue of an additional 31,667 warrants on the same terms.
The funds will be used to support the completion of the current clinical trial for its lead compound Milciclib (an update on which was announced on 8 December 2017), and on development costs for Foralumab, the anti-CD3 antibody.
In addition, it has come to the Company's attention that an error was made in calculating shares due to former holders of convertible loan notes, which resulted in a total of 810,201 shares not being issued to a small number of former note holders in the conversion announced on 16 August 2017 ("Outstanding Loan Note Shares").
Application has been made to the London Stock Exchange plc to admit the Placing Shares and Outstanding Loan Note Shares to trading on AIM with admission expected to occur on 20 December 2017. These shares will rank pari passu with the existing ordinary shares of nominal value 3p each in the capital of the Company (the "Ordinary Shares"). Following the issue of the Placing Shares and Outstanding Loan Note Shares, the enlarged issued share capital of the Company will comprise 125,054,805 Ordinary Shares.
The Company has granted options over a total of 10,717,403 Ordinary Shares of which 5,085,833 are vested at exercise prices between 15p and £1.25p per share and 5,631,570 remain subject to vesting conditions (at potential exercise prices ranging from 15p to £1.925 per share). In addition warrants to subscribe for a total of 4,687,912 Ordinary Shares at exercise prices between 50p and £2.50 are outstanding, including the new warrants granted in the Placing.
Axe,
Obviously you’ve seen this type of contract before... with him being the CEO and it’s his company I guess he had a big hand in drawing them up. He must have felt at the point of signing that this was achievable.
My question is, based on other contracts of other CEO’s you’ve seen, what is the achievable probability to deliver? Put aside your affiliation of TILS for now. Can you give an unbiased answer please?
Even with STEM being split, likelihood it’ll still stay under the TILS group so I’m assuming this £3 will carry forward as a collective. Split or no split, a combined £3 works for me.
Safy, to answer this - Yes. It's going to be slightly complicated because of the Spin Off but I'm sure in the next General Meeting a Special Resolution will be past by the Remuneration Committee to account for this.
So basically for him to benefit to the maximum he needs the SP to be above £3 for 3 months?
Totally back GC, the team the progression of the drugs and his share package screams show me the money
Invest sit back and ignore the noise
also dyor GLA
The Company has a great long-term incentive plan, I only picked out Cerrone's package as it provides an insight in how much he stands to gain is the SP goes in a certain direction - UP
He has options over 3,809,403 Ordinary Shares, at an exercise price of 35p, to Gabriele Cerrone, the
Company's Executive Chairman, split into two component parts:
(i) 3,259,703 options vest if the volume weighted share price of the ordinary shares exceeds
£3.00 (or if the ADS price exceeds the US$ equivalent of £15.00) for 120 consecutive
trading days. These options have a life of 8 years, after which any unvested or unexercised
element will lapse; and
(ii) 550,000 options vest if the volume weighted share price of the ordinary shares exceeds
£1.635 (or if the ADS price exceeds the US$ equivalent of £8.175) for 5 consecutive
trading days. These options have a life of 8 years, after which any unvested or unexercised
element will lapse.